KLF4 Promotes Cisplatin Resistance by Activating MTORC1 Signaling in Ovarian Cancer

Overview

Journal Discov Oncol

Publisher Springer

Specialty Oncology

Date 2024 Nov 20

PMID 39565445

Authors

Wanzhen Zhou

Huixian Huang

Yincheng Teng

Rong Hua

Yan Hu

Xiao Li

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer (OC) is a highly fatal gynecological malignancy worldwide, and cisplatin (CDDP) is commonly used as an initial chemotherapy treatment for OC. Nonetheless, most patients ultimately face recurrence because of resistance to cisplatin. Therefore, it is imperative to investigate the underlying mechanisms of drug resistance in OC. By analyzing differential gene expression using TCGA, GDSC, and GEO public databases, we discovered that increased KLF4 expression is strongly linked to chemotherapy resistance and unfavorable outcomes in OC. Subsequent validation through immunohistochemistry and western blotting confirmed the upregulated KLF4 expression in cisplatin-resistance OC cells lines and tissues. To investigate the function of KLF4, functional experiments were performed both in vitro and in vivo. We observed that knocking down KLF4 impaired cisplatin-resistance of OC. Further mechanism research based on RNA-seq and gene enrichment analysis revealed that interfering KLF4 suppressed the activation of mTORC1 pathway. Finally, rescue experiment demonstrated that using mTORC1 pathway inhibitor could attenuate the cisplatin resistance induced by the overexpression of KLF4. In conclusion, our research indicates that KLF4 promotes cisplatin resistance through the activation of mTORC1 signaling, and proposes that inhibiting KLF4 might serve as a viable therapeutic approach to overcoming drug resistance in ovarian cancer.

References

Mao X, Wang L, Chen Z, Huang H, Chen J, Su J . SCD1 promotes the stemness of gastric cancer stem cells by inhibiting ferroptosis through the SQLE/cholesterol/mTOR signalling pathway. Int J Biol Macromol. 2024; 275(Pt 2):133698. DOI: 10.1016/j.ijbiomac.2024.133698. View

Lheureux S, Gourley C, Vergote I, Oza A . Epithelial ovarian cancer. Lancet. 2019; 393(10177):1240-1253. DOI: 10.1016/S0140-6736(18)32552-2. View

Song M, Cui M, Liu K . Therapeutic strategies to overcome cisplatin resistance in ovarian cancer. Eur J Med Chem. 2022; 232:114205. DOI: 10.1016/j.ejmech.2022.114205. View

Yuce K, Ozkan A . The kruppel-like factor (KLF) family, diseases, and physiological events. Gene. 2023; 895:148027. DOI: 10.1016/j.gene.2023.148027. View

Wang R, Yu W, Zhu T, Lin F, Hua C, Ru L . MED27 plays a tumor-promoting role in breast cancer progression by targeting KLF4. Cancer Sci. 2023; 114(6):2277-2292. PMC: 10236612. DOI: 10.1111/cas.15757. View

Bai J, Chen Y, Sun Y, Wang X, Wang Y, Guo S . EphA2 promotes the transcription of KLF4 to facilitate stemness in oral squamous cell carcinoma. Cell Mol Life Sci. 2024; 81(1):278. PMC: 11335203. DOI: 10.1007/s00018-024-05325-w. View

Pandya A, Talley L, Frost A, Fitzgerald T, Trivedi V, Chakravarthy M . Nuclear localization of KLF4 is associated with an aggressive phenotype in early-stage breast cancer. Clin Cancer Res. 2004; 10(8):2709-19. DOI: 10.1158/1078-0432.ccr-03-0484. View

Zeng L, Zhu Y, Moreno C, Wan Y . New insights into KLFs and SOXs in cancer pathogenesis, stemness, and therapy. Semin Cancer Biol. 2023; 90:29-44. PMC: 10023514. DOI: 10.1016/j.semcancer.2023.02.003. View

Zhang M, Wang J, Guo Y, Yue H, Zhang L . Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer. J Ovarian Res. 2023; 16(1):240. PMC: 10729389. DOI: 10.1186/s13048-023-01314-y. View

10.

Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J . Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020; 5(1):8. PMC: 7005297. DOI: 10.1038/s41392-020-0110-5. View

11.

Tuo Z, Liang L, Zhou R . LINC00852 is associated with poor prognosis in non-small cell lung cancer patients and its inhibition suppresses cancer cell proliferation and chemoresistance via the hsa-miR-145-5p/KLF4 axis. J Gene Med. 2021; 23(12):e3384. DOI: 10.1002/jgm.3384. View

12.

Shen W, Zhang Y . RPN1 promotes the proliferation and invasion of breast cancer cells by activating the PI3K/AKT/mTOR signaling pathway. Discov Oncol. 2024; 15(1):25. PMC: 10834897. DOI: 10.1007/s12672-024-00875-8. View

13.

Wang X, Xia S, Li H, Wang X, Li C, Chao Y . The deubiquitinase USP10 regulates KLF4 stability and suppresses lung tumorigenesis. Cell Death Differ. 2019; 27(6):1747-1764. PMC: 7244734. DOI: 10.1038/s41418-019-0458-7. View

14.

Szwed A, Kim E, Jacinto E . Regulation and metabolic functions of mTORC1 and mTORC2. Physiol Rev. 2021; 101(3):1371-1426. PMC: 8424549. DOI: 10.1152/physrev.00026.2020. View

15.

Chang H, Yang C, Loi L, Hung C, Wu C, Lin Y . Interplay of p62-mTORC1 and EGFR signaling promotes cisplatin resistance in oral cancer. Heliyon. 2024; 10(6):e28406. PMC: 10979205. DOI: 10.1016/j.heliyon.2024.e28406. View

16.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

17.

Yuan L, Meng Y, Xiang J . KLF4 Induces Colorectal Cancer by Promoting EMT via STAT3 Activation. Dig Dis Sci. 2024; 69(8):2841-2855. DOI: 10.1007/s10620-024-08473-y. View

18.

Kaczynski J, Cook T, Urrutia R . Sp1- and Krüppel-like transcription factors. Genome Biol. 2003; 4(2):206. PMC: 151296. DOI: 10.1186/gb-2003-4-2-206. View

19.

Yang L, Xie H, Li Y, Wang X, Liu X, Mai J . Molecular mechanisms of platinum‑based chemotherapy resistance in ovarian cancer (Review). Oncol Rep. 2022; 47(4). PMC: 8908330. DOI: 10.3892/or.2022.8293. View

20.

Konstantinopoulos P, Matulonis U . Clinical and translational advances in ovarian cancer therapy. Nat Cancer. 2023; 4(9):1239-1257. DOI: 10.1038/s43018-023-00617-9. View